User:Mr. Ibrahem/Sutimlimab
humanized hybrid | |
|---|---|
| Target | complement component 1s |
| Clinical data | |
| Trade names | Enjaymo |
| Other names | BIVV009, sutimlimab-jome |
| AHFS/Drugs.com | Monograph |
| License data |
|
Intravenous infusion | |
| Legal status | |
| Legal status | |
Sutimlimab, sold under the brand name Enjaymo, is a medication used to treat
encapsulated bacteria before it is started.[1]
Common side effects include
C1s.[2]
Sutimlimab was approved for medical use in the United States and Europe in 2022.[1][2] In the United States it costs about 280,000 USD per year for someone who weights 40 to 75 kg.[3] It is not marketed in the United Kingdom.[3]
References
- ^ a b c d e f g h i "Enjaymo- sutimlimab injection, solution, concentrate". DailyMed. 1 February 2022. Archived from the original on 21 February 2022. Retrieved 20 February 2022.
- ^ a b c "Enjaymo". Archived from the original on 6 December 2022. Retrieved 11 December 2022.
- ^ a b "Sutimlimab". SPS - Specialist Pharmacy Service. 19 October 2018. Archived from the original on 5 July 2022. Retrieved 11 December 2022.